VSee Health (VSEE) AI Stock Analysis

• Market Cap: $17.36M
• Dividend Yield: N/A
• Average Volume (3M): 1.90M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.18
• Revenue Growth: 187.24%
• EPS Growth: 82.90%
• Country: US
• Employees: 2
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): N/A
• Shares Outstanding: 17,022,690
• 10 Day Avg. Volume: 5,577,105
• 30 Day Avg. Volume: 1,899,699
• PEG Ratio: >-0.01
• Price to Book (P/B): -751.28
• Price to Sales (P/S): 1.33
• P/FCF Ratio: -2.38
• Enterprise Value/Market Cap: 1.75
• Enterprise Value/Revenue: 2.09
• Enterprise Value/Gross Profit: 3.83
• Enterprise Value/Ebitda: -5.49
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 40 Underperform
• Price Target: $0.50 ▼(-23.08% Downside)

VSee Health's overall stock score is primarily impacted by its poor financial performance and weak technical indicators. The company's negative equity and ongoing losses are significant concerns, and the bearish technical signals further weigh on the stock's outlook. The lack of positive valuation metrics compounds these issues, resulting in a low overall score.

VSee Health Business Overview & Revenue Model

Company Description

VSee Health, Inc. provides telehealth care solutions. The company offers iDoc Telehealth solutions that treat and coordinate care for acutely ill patients in the neurointensive care, cardiac intensive care, and intensive care units for stroke, spinal cord, brain trauma, and other neurological conditions. Its telehealth platform provides a set of building blocks to solve needs of clients. VSee Health, Inc. is headquartered in Newton, Massachusetts.

How the Company Makes Money

VSee generates revenue through multiple streams, primarily by offering subscription-based services to healthcare providers and organizations. The company charges clients a monthly or annual fee for access to its telehealth platform, which can vary based on the features and number of users. Additionally, VSee may earn revenue through transaction fees for specific telehealth services, as well as through partnerships with healthcare systems and organizations that integrate its technology into their operations. Significant partnerships with hospitals, clinics, and telehealth networks further enhance its market reach and contribute to its earnings.

VSee Health Financial Statement Overview

Summary

VSee Health is facing significant financial challenges across all verticals. Despite some revenue growth, the company struggles with profitability and has a precarious balance sheet with negative equity. Cash flow improvements are insufficient to offset the broader financial instability. The company needs to address its operational inefficiencies and strengthen its financial position to ensure long-term viability.

Income Statement

VSee Health's income statement reveals a challenging financial position. The company has experienced revenue growth in the TTM period, but it is accompanied by negative profit margins, including a significant net profit margin of -4.59%. The EBIT and EBITDA margins are also negative, indicating operational inefficiencies. While there is some revenue growth, the persistent losses are a concern.

Balance Sheet

The balance sheet shows a negative stockholders' equity, which is a significant red flag. The debt-to-equity ratio is negative due to the negative equity, and the return on equity is misleadingly positive because of the negative equity base. The equity ratio is also negative, indicating financial instability and potential solvency issues.

Cash Flow

Cash flow analysis indicates some improvement in free cash flow growth, but the company still faces negative operating cash flow. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings, but the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.55M	10.42M	5.77M	6.38M	7.34M	6.80M
Gross Profit	7.95M	7.18M	3.83M	4.84M	5.92M	5.46M
EBITDA	-5.55M	-3.36M	-1.79M	0.00	0.00	0.00
Net Income	-12.48M	-57.70M	-3.76M	-836.21K	475.90K	258.88K
Balance Sheet
Total Assets	18.71M	19.99M	805.79K	2.61M	117.94M	2.73M
Cash, Cash Equivalents and Short-Term Investments	472.76K	326.12K	118.73K	230.66K	760.01K	775.24K
Total Debt	3.46M	9.55M	543.00K	517.13K	0.00	133.08K
Total Liabilities	24.28M	20.01M	5.11M	2.61M	4.55M	2.11M
Stockholders Equity	-5.58M	-18.49K	-3.97M	360.72K	113.39M	614.49K
Cash Flow
Free Cash Flow	-4.52M	-5.84M	-636.93K	-1.45M	-600.11K	789.12K
Operating Cash Flow	-4.49M	-5.79M	-632.60K	-1.45M	-600.11K	789.12K
Investing Cash Flow	-27.54K	-26.14K	-4.33K	110.12M	-116.73M	0.00
Financing Cash Flow	2.67M	6.02M	525.00K	-109.32M	118.09M	-83.67K

VSee Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VSEE, the sentiment is Negative. The current price of 0.65 is below the 20-day moving average (MA) of 0.87, below the 50-day MA of 0.73, and below the 200-day MA of 1.07, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 43.39 is Neutral, neither overbought nor oversold. The STOCH value of 18.08 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VSEE.

VSee Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AMWL	48 Neutral	$81.57M	―	-38.35%	―	4.33%	50.50%
TDOC	47 Neutral	$1.29B	―	-15.42%	―	-2.37%	77.85%
ZCMD	43 Neutral	$14.14M	―	-8.96%	―	-24.64%	92.19%
VSEE	40 Underperform	$17.36M	-0.24	―	―	187.24%	82.90%

VSee Health Corporate Events

VSee Health Enters Warrant Exchange Agreement

On October 29, 2025, VSee Health, Inc. entered into a warrant exchange agreement with an institutional investor, resulting in the exercise of approximately 130,000 outstanding warrants for cash and the exchange of 2,250,000 warrants for 2,175,000 shares of common stock. This agreement, governed by the Securities Act of 1933, imposes restrictions on the company’s ability to issue new stock or equivalents and undertake certain corporate actions for ten days following the agreement, potentially impacting its market strategy and stakeholder interests.

The most recent analyst rating on (VSEE) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.

VSee Health Announces 2025 Annual Stockholders Meeting

VSee Health, Inc. has announced that its 2025 annual meeting of stockholders will be held on December 15, 2025, with November 20, 2025, set as the record date for determining eligible stockholders. The company has outlined the deadlines and requirements for stockholder proposals and proxy solicitations, emphasizing the importance of meeting the November 7, 2025, deadline for inclusion in the proxy materials and compliance with SEC regulations.

The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.

VSee Health Amends Convertible Promissory Note

On October 21, 2025, VSee Health, Inc. amended its senior secured convertible promissory note, originally issued on September 30, 2024, to redefine the ‘Conversion Price’ to $0.75. This amendment maintains all other terms of the note, potentially impacting the company’s financial strategy and investor relations.

The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.

VSee Health Secures New Note Purchase Agreement

On October 20, 2025, VSee Health, Inc. entered into a note purchase agreement with an accredited institutional investor, issuing a secured note worth $133,333.33 at a purchase price of $120,000. The note, which bears a 5% annual interest rate and matures on May 20, 2026, includes standard default provisions and restrictions on variable rate transactions and exchange transactions involving the company’s debt or securities. Additionally, on the same date, VSee Health amended previous security agreements to ensure the note is fully secured by the company’s assets. On October 18, 2025, the company terminated an Equity Purchase Agreement from November 21, 2023, with another accredited institutional investor.

The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.

VSee Health Secures New Note Purchase Agreement

On October 9, 2025, VSee Health, Inc. entered into a note purchase agreement with an accredited institutional investor, issuing a secured note for $133,333.33 with a purchase price of $120,000, bearing an interest rate of 5% per annum and maturing on May 8, 2026. The agreement includes restrictions on variable rate transactions and mandates equal terms for future debt holders, while an amendment agreement ensures the note is fully secured by the company’s assets, potentially strengthening VSee Health’s financial stability and market position.

The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.

VSee Health Appeals Nasdaq Delisting Notice

On August 5, 2025, VSee Health, Inc. received a notice from Nasdaq indicating a potential suspension of its stock and warrants due to non-compliance with listing rules, including failure to timely file financial reports and insufficient stockholders’ equity. The company is appealing the decision and plans to address these deficiencies in a hearing scheduled for September 9, 2025. If the appeal is unsuccessful, VSee Health’s securities may be delisted, potentially limiting market access and affecting trading prices.

The most recent analyst rating on (VSEE) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.

VSee Health Faces Nasdaq Delisting Notice

VSee Health, Inc. received a notice from Nasdaq on August 20, 2025, for non-compliance with listing rules due to delayed filing of required reports with the SEC. The company is scheduled for a hearing on September 9, 2025, to appeal the decision to delist its stock and warrants from Nasdaq, with trading expected to move to OTC Markets if delisting proceeds. The potential delisting could limit market accessibility for shareholders and affect stock prices.

The most recent analyst rating on (VSEE) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on VSee Health stock, see the VSEE Stock Forecast page.